High-alert medicines: layered safeguards beyond a double check

High alert describes potential harm

ISMP defines high-alert medicines by the substantial harm that may occur when they are used incorrectly; errors are not necessarily more frequent. ^[1] Prioritization should therefore consider the possible consequence and actual medication pathway, rather than incident counts alone.

Look beyond the product

WHO identifies medicine-related, provider or patient, and system or work-environment factors in high-risk situations. ^[2] ISMP discusses multiple safeguards and cautions that a manual independent double check is not automatically the best strategy for every high-alert medicine. ^[1]

An ICORP implementation proposal

Have the medication safety committee choose priorities relevant to the hospital. Trace a selected process from prescribing through preparation, administration and monitoring. Identify which controls prevent selection errors, which detect them before reaching a patient, and which support follow-up. Product-specific decisions should be approved by the responsible clinical and pharmacy leaders.

Review safeguards in practice

Possible review points include bypassed alerts, checks performed together rather than independently, and workload barriers that encourage shortcuts. Consider intercepted errors and staff feedback together. This article supplies no doses, concentrations or treatment instructions and does not treat a High Alert label as proof of a safe system.